Live Breaking News & Updates on Vesper Life Sciences
Stay updated with breaking news from Vesper life sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
PNB Vesper gets DCGI nod to conduct Ph III trials on COVID-19 drug biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
The city-based PNB Vesper Life Sciences has successfully completed phase 2 clinical trials of PNB-001 (GPP-Baladol), its proprietary drug to treat the coronavirus infection and said it will soon move the government for deploying the drug for emergency use. The company, which has its labs in England, had in early September 2020 received the approval from the Drug Controller General (DCGI) to conduct the phase 2 clinical trial of GPP-Baladol in patients with moderate infection of the pandemic with oxygen support. The company on Monday said the clinical trial was initiated in November at BJ Government Medical College and Sassoon General Hospital in Pune, and Victoria Medical College and Research Institute in Bengaluru on 40 patients. ....
Kochi-based pharma firm s new drug shows promising results against COVID-19 The trial was conducted on 40 patients since November at BJ Government Medical College and Sassoon General Hospital Pune and Victoria Medical College and Research Institute, Bangalore PB Jayakumar | February 22, 2021 | Updated 15:08 IST GPP-Baladol, a novel chemical entity (NCE) being developed by pharmaceutical research firm PNB Vesper Life Science for treating Covid-19 patients, claims to have shown promising results in the Phase 2b clinical trials. The pharma firm will soon seek Indian drug regulators approval for emergency use in the country. The trial was conducted on 40 patients since November at BJ Government Medical College and Sassoon General Hospital Pune and Victoria Medical College and Research Institute, Bangalore. The clinical trial report will be submitted to the DCGI today seeking for an Emergency Use Authorisation to treat hospitalised patients in the country in a ....
Kochi firm PNB Vesper Life completes Phase 2 clinical trial of COVID-19 drug The company, which has its labs in England, had in early September 2020 received the approval from the Drug Controller General (DCGI) to conduct the phase 2 clinical trial of GPP-Baladol in patients with moderate infection of the pandemic with oxygen support PTI | February 22, 2021 | Updated 17:13 IST The city-based PNB Vesper Life Sciences has successfully completed phase 2 clinical trials of PNB-001 (GPP-Baladol), its proprietary drug to treat the coronavirus infection and said it will soon move the government for deploying the drug for emergency use. The company, which has its labs in England, had in early September 2020 received the approval from the Drug Controller General (DCGI) to conduct the phase 2 clinical trial of GPP-Baladol in patients with moderate infection of the pandemic with oxygen support. ....
PNB Vesper provides potential option to save hospitalised COVID-19 patients globally PNB Vesper provides potential option to save hospitalised COVID-19 patients globally 12 February 2021 | News Source credit: Shutterstock PNB Vesper, a leading Kerala based life sciences company, has announced that it has successfully completed the phase 2 clinical trials of its proprietary drug PNB-001 (GPP-Baladol) on COVID-19 patients. The company had received approval from the Drug Controller General of India (DCGI) to conduct the Phase 2 Clinical trial of GPP-BALADOL in COVID-19 moderate patients with oxygen support in September 2020. The clinical trial was initiated in November 2020 at BJ Government Medical College and Sassoon General Hospital Pune, and Victoria Medical College and Research Institute, Bengaluru. The clinical trial report will now be submitted to DCGI on February 22, 2021. ....